Kian-Huat Lim

Dr. Kian-Huat Lim

Washington University School of Medicine St. Louis, MO, USA
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2010 in Nature
Verified
Journal Article
Closed access
PDF file
VNVu N. Ngo
Vu N. Ngo
RYRyan M. Young
Ryan M. Young
RSRoland Schmitz
Roland Schmitz
SJSameer Jhavar
Sameer Jhavar
WXWenming Xiao
Wenming Xiao
LSLouis M. Staudt
Louis M. Staudt

1 May 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
TNTimothy M Nywening
Timothy M Nywening
AWAndrea Wang-Gillam
Andrea Wang-Gillam
DSDominic E Sanford
Dominic E Sanford
BBBrian A Belt
Brian A Belt
RPRoheena Z Panni
Roheena Z Panni
DLDavid C Linehan
David C Linehan

1 January 2013 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Open access
PDF file
KLKian-Huat Lim
Kian-Huat Lim
LSLouis M. Staudt
Louis M. Staudt
A new type of review journal, featuring comprehensive collections of expert review articles on important topics in the molecular life sciences

15 July 2007 in Genes & Development
Verified
Journal Article
Closed access
PDF file
BABrooke Ancrile
Brooke Ancrile
KLKian-Huat Lim
Kian-Huat Lim
CCChristopher M. Counter
Christopher M. Counter
Ras is mutated to remain in the active oncogenic state in many cancers. As Ras has proven difficult to target therapeutically, we searched for secreted, druggable proteins induced by Ras that are required for tumorigenesis. We found that Ras induces the secretion of cytokine IL6 in different cell types, and that knockdown of IL6, genetic ablation of theIL6gene, or treatment with a neutralizing IL6 antibody retard Ras-driven tumorigenesis. IL6 appears to act in a paracrine fashion to promote angiogenesis and tumor growth. Inhibiting IL6 may therefore have therapeutic utility for treatment of cancers characterized by oncogenic Ras mutations.

7 August 2011 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
DKDavid Kashatus
David Kashatus
KLKian-Huat Lim
Kian-Huat Lim
DBDonita C. Brady
Donita C. Brady
NPNicole L. K. Pershing
Nicole L. K. Pershing
ACAdrienne D. Cox
Adrienne D. Cox
CCChristopher M. Counter
Christopher M. Counter
Mitotic mitochondrial fission requires CDK1-mediated phosphorylation of DRP1. The Aurora A substrate RALA is found to concentrate DRP1 and RALBP1 at mitochondria to promote DRP1 phosphorylation and fission. Mitochondria exist as dynamic interconnected networks that are maintained through a balance of fusion and fission1. Equal distribution of mitochondria to daughter cells during mitosis requires fission2. Mitotic mitochondrial fission depends on both the relocalization of the large GTPase DRP1 to the outer mitochondrial membrane and phosphorylation of Ser 616 on DRP1 by the mitotic kinase cyclin B–CDK1 (ref. 2). We now report that these processes are mediated by the small Ras-like GTPase RALA and its effector RALBP1 (also known as RLIP76, RLIP1 or RIP1; refs 3, 4). Specifically, the mitotic kinase Aurora A phosphorylates Ser 194 of RALA, relocalizing it to the mitochondria, where it concentrates RALBP1 and DRP1. Furthermore, RALBP1 is associated with cyclin B–CDK1 kinase activity that leads to phosphorylation of DRP1 on Ser 616. Disrupting either RALA or RALBP1 leads to a loss of mitochondrial fission at mitosis, improper segregation of mitochondria during cytokinesis and a decrease in ATP levels and cell number. Thus, the two mitotic kinases Aurora A and cyclin B–CDK1 converge on RALA and RALBP1 to promote mitochondrial fission, the appropriate distribution of mitochondria to daughter cells and ultimately proper mitochondrial function.

1 June 2005 in Cancer Cell
Verified
Journal Article
Closed access
KLKian-Huat Lim
Kian-Huat Lim
ABAntonio T. Baines
Antonio T. Baines
JFJames J. Fiordalisi
James J. Fiordalisi
MSMichail Shipitsin
Michail Shipitsin
LFLarry A. Feig
Larry A. Feig
CCChristopher M. Counter
Christopher M. Counter